![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
|
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
624kB |
| Item Type: | Article |
|---|---|
| Title: | ISN Nexus 2016 Symposia: translational immunology in kidney disease -- the Berlin roadmap |
| Creators Name: | Anders, H.J. and Rovin, B. and Jayne, D. and Brunetta, P. and Coppo, R. and Davidson, A. and Devarapu, S.K. and de Zeeuw, D. and Duffield, J. and Eulberg, D. and Fierro, A. and Floege, J. and Frese, S. and Guillevin, L. and Holdsworth, S. and Hughes, J. and Kettritz, R. and Kluger, M. and Krebs, C. and Lapteva, L. and Levin, A. and Li, J. and Lightstone, L. and Mack, M. and Mansouri, L. and McAdoo, S. and McKinney, E. and Panzer, U. and Parikh, S. and Pusey, C. and Putterman, C. and Rabelink, T. and Radbruch, A. and Rees, A. and Reilly, M. and Reinders, M. and Remuzzi, G. and Ruggenenti, P. and Sacks, S. and Schall, T.J. and Meyer-Schwesinger, C. and Sharma, K. and Suzuki, Y. and Tomas, N.M. and Zhao, M.H. |
| Abstract: | To date, the treatment of immune-mediated kidney diseases has only marginally benefited from highly specific biological drugs that have demonstrated remarkable effects in many other diseases. What accounts for this disparity? In April 2016, the International Society of Nephrology held a Nexus meeting on Translational Immunology in Nephrology in Berlin, Germany, to identify and discuss hurdles that block the translational flow of target identification, and preclinical and clinical target validation in the domain of immune-mediated kidney disease. A broad panel of experts including basic scientists, translational researchers, clinical trialists, pharmaceutical industry drug developers, and representatives of the American and European regulatory authorities made recommendations on how to overcome such hurdles at all levels of the translational research process. The results of these discussions are presented here, which may serve as a roadmap for how to optimize the process of developing more innovative and effective drugs for patients with immune-mediated kidney diseases. |
| Keywords: | Autoimmunity, Inflammation, Lupus, Rejection, Stem Cells, Vasculitis |
| Source: | Kidney International Reports |
| ISSN: | 2468-0249 |
| Publisher: | Elsevier |
| Volume: | 1 |
| Number: | 4 |
| Page Range: | 327-339 |
| Date: | November 2016 |
| Official Publication: | https://doi.org/10.1016/j.ekir.2016.06.009 |
Repository Staff Only: item control page
Download Statistics
Download Statistics
